Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Accumulated Expenses (2021 - 2025)

Kezar Life Sciences' Accumulated Expenses history spans 5 years, with the latest figure at $6.1 million for Q1 2025.

  • For Q1 2025, Accumulated Expenses fell 8.24% year-over-year to $6.1 million; the TTM value through Mar 2025 reached $6.1 million, down 8.24%, while the annual FY2024 figure was $7.9 million, N/A changed from the prior year.
  • Accumulated Expenses for Q1 2025 was $6.1 million at Kezar Life Sciences, down from $7.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.7 million in Q3 2023 and bottomed at $5.0 million in Q4 2021.
  • The 5-year median for Accumulated Expenses is $6.8 million (2023), against an average of $7.6 million.
  • The largest annual shift saw Accumulated Expenses grew 19.42% in 2022 before it dropped 9.32% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $5.0 million in 2021, then rose by 19.42% to $6.0 million in 2022, then soared by 79.02% to $10.7 million in 2023, then decreased by 25.54% to $7.9 million in 2024, then fell by 22.94% to $6.1 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Accumulated Expenses are $6.1 million (Q1 2025), $7.9 million (Q4 2024), and $9.7 million (Q3 2024).